Despite significant therapeutic advances, patients with chronic heart failure and reduced ejection fraction (HFrEF) remain at high risk for heart failure progression and death. The PARADIGM-HF study, the largest outcome trial in HFrEF, has shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), previously known as LCZ696, compared with angiotensin-converting enzyme (ACE) inhibitor therapy, possibly leading us to a new era for heart failure treatment. Sacubitril/valsartan represents a first-in-class drug acting through inhibition of angiotensin receptor and neprilysin, thus modulating the renin-angiotensin-aldosterone system and vasoactive substances such as natriuretic peptides. This approach can be considered a "paradigm shift" from neurohumoral inhibition to neurohumoral modulation. Based on the PARADIGM-HF results, the European Society of Cardiology and the American Heart Association/American College of Cardiology guidelines proposed a substitution of ACE-inhibitor/angiotensin receptor blocker therapy rather than an "add-on" strategy in HFrEF. Sacubitril/valsartan can be considered a milestone in cardiovascular therapy, like aspirin, statins, beta-blockers. Of course there are many questions that arise spontaneously from this trial, three recognized experts can help us to answer them.

Senni, M., Trimarco, B., Emdin, M., & De Biase, L. (2017). Sacubitril/valsartan, a new and effective treatment of heart failure with reduced ejection fraction [Sacubitril/valsartan, una nuova ed efficace terapia dello scompenso cardiaco a funzione sistolica ridotta]. GIORNALE ITALIANO DI CARDIOLOGIA, 18(1), S3-S11.

Sacubitril/valsartan, a new and effective treatment of heart failure with reduced ejection fraction [Sacubitril/valsartan, una nuova ed efficace terapia dello scompenso cardiaco a funzione sistolica ridotta]

Senni M
;
2017

Abstract

Despite significant therapeutic advances, patients with chronic heart failure and reduced ejection fraction (HFrEF) remain at high risk for heart failure progression and death. The PARADIGM-HF study, the largest outcome trial in HFrEF, has shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), previously known as LCZ696, compared with angiotensin-converting enzyme (ACE) inhibitor therapy, possibly leading us to a new era for heart failure treatment. Sacubitril/valsartan represents a first-in-class drug acting through inhibition of angiotensin receptor and neprilysin, thus modulating the renin-angiotensin-aldosterone system and vasoactive substances such as natriuretic peptides. This approach can be considered a "paradigm shift" from neurohumoral inhibition to neurohumoral modulation. Based on the PARADIGM-HF results, the European Society of Cardiology and the American Heart Association/American College of Cardiology guidelines proposed a substitution of ACE-inhibitor/angiotensin receptor blocker therapy rather than an "add-on" strategy in HFrEF. Sacubitril/valsartan can be considered a milestone in cardiovascular therapy, like aspirin, statins, beta-blockers. Of course there are many questions that arise spontaneously from this trial, three recognized experts can help us to answer them.
Articolo in rivista - Articolo scientifico
Aminobutyrates; Cardiovascular Agents; Heart Failure; Humans; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan;
English
S3
S11
Senni, M., Trimarco, B., Emdin, M., & De Biase, L. (2017). Sacubitril/valsartan, a new and effective treatment of heart failure with reduced ejection fraction [Sacubitril/valsartan, una nuova ed efficace terapia dello scompenso cardiaco a funzione sistolica ridotta]. GIORNALE ITALIANO DI CARDIOLOGIA, 18(1), S3-S11.
Senni, M; Trimarco, B; Emdin, M; De Biase, L
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372425
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
Social impact